<DOC>
	<DOCNO>NCT00401947</DOCNO>
	<brief_summary>The purpose study Investigate Safety , Tolerability , Pharmacokinetics Antiviral Activity Multiple Doses ACH-0137171 Subjects Chronic Hepatitis C Infection</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics Antiviral Activity ACH-0137171 Subjects With Chronic Hepatitis C Infection</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , dose escalation study ACH-0137171 subject chronic HCV infection . Sequential cohort 10 subject randomize ( 8:2 ) receive multiple dos ACH-0137171 placebo 4 day ( Days 1 4 ) single dose Day 5 follow complete pharmacokinetic profile . Dosing 300 - 600 mg administer either every 12 hour every 6 hour ( maximum daily dose 2400 mg ) . All dos administer food . The dose cohort follow : Study Schema : Cohort 1 : 300 mg ACH-0137171/placebo every 12 hour ( 600 mg/day ) * Cohort 2 : 300 mg ACH-0137171/placebo every 6 hour ( 1200 mg/day ) * Cohort 3 : 600 mg ACH-0137171/placebo every 6 hour ( 2400 mg/day ) * A full review safety data occur follow cohort . Depending data , Sponsor , consultation Principal Investigator ( ) , may consider modify plan dose escalation . The Sponsor may choose interject intermediate dose cohort 2 plan dose escalation repeat give dose level , extend dose period , add additional cohort . If similar Grade 3 4 adverse event occur three subject , consider least possibly related study drug , escalation high dose occur . Serial HCV RNA measurement , pharmacokinetic measurement plasma concentration ACH-0137171 , periodic safety monitoring occur Days 1 5 . Additional HCV RNA PK measurement take Days 6 9 . Follow safety evaluation complete 14 day last study drug administration ( i.e. , Days 12 19 ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Chronic HCV infection must document positive anti HCV antibody use third generation enzyme immunoassay ( EIA ) persistent detection HCV RNA blood least 6 month . Subjects must infect HCV genotype 1 ( line probe assay ; INNOLiPA HCV II , Innogenetics ) may treatmentnaïve treatmentexperienced ( treatment experience specifically mean prior treatment interferon , standard pegylated , without ribavirin therapy stop &gt; 6 month prior screen ) . In addition , eligible subject must ALT AST &lt; 5 x upper limit normal ( ULN ) , plasma HCV RNA &gt; 5 log10 IU/mL , clinical laboratory evidence hepatic decompensation inclusion ( must platelets &gt; 100,000/mm3 , total bilirubin &lt; 1.5 x ULN , prothrombin time &lt; 1.5 x ULN , albumin &gt; 3.0 g/dL inclusion ) . Women eligible pregnant breastfeeding . Women childbearing potential ( i.e. , surgically sterile confirm post menopausal ) must confirm negative pregnancy test . All subject must practice medically acceptable form contraception describe Section 7.2.1 . HIV HBV coinfection , know cirrhosis , prior history clinical hepatic decompensation ( ascites , jaundice , encephalopathy variceal hemorrhage ) , alcoholic form chronic liver disease , evidence hepatocellular carcinoma ( αfetoprotein &gt; 50 ng/mL ) , creatinine clearance &lt; 80 mL/min ( use CockcroftGault equation ) , hemoglobin &lt; 10 g/dL , neutrophils &lt; 1500/mm3 , abnormal thyroid function test ( TSH &gt; 2.5 µIU/mL , free T4 &gt; ULN ) , , positive test result illicit drug , alcohol , drug abuse within past 12 month . Subjects significant gastrointestinal , thyroid , renal , cardiovascular , pulmonary , oncologic , neurological disease , currently receive immunomodulators ( corticosteroid , etc ) , investigational , nephrotoxic hepatotoxic drug ( e.g phenytoin , carbamazepine , INH , azole antifungal agent ketoconazole , aminoglycoside antibiotic , etc . ) , nonsteroidal antiinflammatory agent , ibuprofen acetaminophen ( daily basis ) also exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>HCV</keyword>
	<keyword>Chronic</keyword>
	<keyword>Hepatitis</keyword>
</DOC>